Union Health Minister Dr Harsh Vardhan, on Sunday, 3 January, took to Twitter to respond to the Opposition’s criticism on the Drugs Controller General of India’s (DCGI) approval for emergency use of the two Indian COVID-19 vaccines – Covaxin and Covishield.
"For those spreading rumours let it be known that EUA (Emergency Use Approval) for COVAXIN is differently conditional – in clinical trial mode,” Dr Vardhan tweeted.
"EUA for COVAXIN is different from COVISHIELD because its use will be in clinical trial mode. All COVAXIN recipients to be tracked, monitored as if they’re in trial,” he added.
"COVAXIN approval is ‘Monitored Approval’ with strict follow-up & rolling review. This approval ensures India has an additional vaccine shield in its arsenal esp against potential mutant strains in a dynamic pandemic situation - A strategic decision for our vaccine security (sic),” he said in another tweet.

